Jun 1, 2026 · Science & Research Daily Digest

Today's science, space, biomed, and climate research highlights for June 1, 2026, with summaries, links, and commentary.

I. Space & Deep Space

1. Cape Canaveral declared “fully mission capable”; Blue Origin regains partial LC-36 access and begins cleanup

Summary:

Per Orbital Today, WESH, and SpaceNews (around June 1, 2026), a Blue Origin New Glenn rocket exploded during a static-fire test at Cape Canaveral’s Launch Complex 36 on the evening of May 28, destroying the ~98 m vehicle, transporter-erector, and a lightning tower; the NG-4 mission (48 Amazon Leo satellites), previously targeted around June 4, is indefinitely postponed. The U.S. Space Force said the Cape range remains “fully mission capable,” with SpaceX and ULA launching Falcon 9 and Atlas V the next day. CEO Dave Limp said on May 30 that partial LC-36 access had been restored and pad clearing would begin soon; integration-facility boosters and upper stages “appear healthy from quick looks.” Analysts note LC-36 is New Glenn’s only operational pad, with repairs estimated at 12–18 months, pressuring NASA Artemis and Blue Moon cargo/lander schedules.

Links:

• Orbital Today — Cape Canaveral Declared ‘Fully Mission Capable’ After Blue Origin New Glenn Explosion
• SpaceNews — New Glenn failure worsens constrained launch market

Commentary:

The range kept flying, but the single-pad bottleneck for heavy New Glenn and lunar logistics is now a shared industry and policy concern one week after the mishap.

II. Biomedicine & Health

2. RASolute 302 keeps dominating headlines: daraxonrasib median OS 13.2 vs 6.7 months in second-line mPDAC

Summary:

Per ScienceAlert (AP), ABC News, and Revolution Medicines (June 1, 2026), global randomized Phase 3 RASolute 302 (NCT06625320) results continue to reverberate after an ASCO plenary and simultaneous NEJM publication. Among 500 patients with previously treated metastatic pancreatic ductal adenocarcinoma randomized 1:1 to oral RAS(ON) multi-selective inhibitor daraxonrasib or investigator’s-choice chemotherapy, intent-to-treat median overall survival (OS) was 13.2 vs 6.7 months (hazard ratio ~0.40), median progression-free survival (PFS) 7.2 vs 3.6 months, and treatment-related discontinuation 1.2% vs 11.2%. Dana-Farber’s Brian Wolpin called for a new second-line standard and exploration in earlier disease and surgery windows; FDA expanded access was authorized May 1, with expedited review planned.

Links:

• ScienceAlert — Breakthrough Pill Nearly Doubles Survival Time For One of The Deadliest Cancers
• NEJM — Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer

Commentary:

With >90% of PDAC RAS-driven and long “undruggable,” the first Phase 3 RAS(ON) inhibitor to beat chemotherapy in second line could reset standards and force earlier-line and perioperative trials.

3. HARMONi-6 plenary: ivonescimab (PD-1/VEGF bispecific) plus chemo improves first-line sq-NSCLC OS (HR=0.66)

Summary:

Per BioSpace, Akeso, and PRNewswire (June 1, 2026), Phase III HARMONi-6/AK112-306 OS data were presented at the 2026 ASCO plenary: 532 treatment-naïve advanced squamous NSCLC patients received ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy. Prespecified interim analysis showed a 34% reduction in death risk (HR=0.66, 95% CI 0.50–0.87, P=0.0017), median OS 27.9 vs 23.7 months, 24-month OS rates 64.7% vs 48.6%, median follow-up ~21.4 months. Prior PFS analysis showed medians 11.1 vs 6.9 months (HR=0.60). The trial is described as the first Phase III in lung cancer to show statistically significant OS and PFS benefits versus PD-1 plus chemotherapy.

Links:

• BioSpace — Ivonescimab OS Benefit in HARMONi-6 (June 1, 2026)
• Akeso — HARMONi-6 OS Results at ASCO 2026 Plenary

Commentary:

Beating PD-1 plus chemo with a PD-1/VEGF bispecific supplies top-tier evidence for dual-pathway synergy over “stack another PD-1.”

4. LIBRETTO-432 at ASCO plenary and in NEJM: adjuvant selpercatinib cuts early RET fusion-positive NSCLC EFS risk by 83%

Summary:

Per Lilly, BioSpace, and Newswise (June 1, 2026), global Phase III LIBRETTO-432 was presented at ASCO and published in NEJM: 151 stage IB–IIIA RET fusion-positive NSCLC patients after definitive locoregional therapy were randomized to selpercatinib or placebo for up to three years. In the primary population (stage II–IIIA, n=109), investigator-assessed event-free survival (EFS) improved sharply, with an 83% lower risk of recurrence or death (HR=0.17, P<0.001); 24-month EFS rates were 92% vs 61%, median EFS not reached vs 31.8 months. Results were consistent in the overall IB–IIIA population. RET fusions account for roughly 1%–2% of NSCLC; no approved adjuvant targeted therapy existed previously.

Links:

• BioSpace — Lilly's Retevmo demonstrated 83% reduction in recurrence risk (June 1, 2026)
• Newswise — Targeted therapy reduces lung cancer recurrence risk by 83%

Commentary:

Adjuvant RET inhibition in early disease could drive routine postoperative molecular testing and guideline updates for a rare but actionable subtype.

5. ETH Zurich and University of Basel: phage-steered triple therapy clears gut E. coli K1 in pregnancy, cutting neonatal meningitis transmission

Summary:

Per ETH Zurich (June 1, 2026), neonatal meningitis pathogen E. coli K1 often colonizes adult intestines and can pass to preterm infants at birth. Because the K1 capsule resembles human cells, conventional vaccines are difficult. Researchers combined phages isolated from Lucerne wastewater treatment effluent (forcing bacteria to shed the K1 capsule), oral vaccination to raise intestinal antibodies, and a benign probiotic to occupy the niche. In infected pregnant mice, transmission fell from 83% of offspring in controls to 23% with triple therapy. Results appear in Nature Communications (2026, 17:4363, DOI 10.1038/s41467-026-70808-2); a human swallowable capsule is planned, with extension to other resistant gut pathogens.

Links:

• ETH Zurich — Protection for newborns: new treatment aims to prevent meningitis without antibiotics
• Nature Communications — Phage-steering permits antibody-mediated clearance of E. coli K1 from the gut

Commentary:

Linking phage-driven decapsulation, mucosal immunity, and ecological displacement offers an engineerable, antibiotic-sparing path for neonatal infection control.

III. Climate, Energy & Environment

6. Tandem PV: 30.4% internal efficiency on 100 cm² perovskite/silicon 4T demo module, entering third-party certification

Summary:

Per pv magazine USA (June 1, 2026), U.S. Tandem PV reached 30.4% conversion efficiency on a 100 cm² demonstration module: proprietary 4-terminal perovskite glass atop a Maxeon interdigitated back-contact (IBC) silicon cell, with processes aimed at production rather than lab-scale cells. CEO Scott Wharton said full-size modules could reach ~28% later in 2026—~12% more output per area than a leading ~25% 545 W back-contact module—targeting utility-scale markets; the perovskite layer alone contributes ~9% absolute efficiency, and third-party certification is underway. The Fremont, California demo factory is operating; accelerated aging suggests ~1%/year degradation at 65 °C, and former Energy Secretary Jennifer Granholm joined the board.

Links:

• pv magazine USA — Tandem PV announces 30.4% efficient perovskite/silicon demonstration module
• Business Wire — Tandem PV Opens California Factory for Next-Generation Solar Manufacturing

Commentary:

Tandem modules crossing 30% on a manufacturable route, if certification and field degradation hold, could accelerate utility PV LCOE declines.

7. Trina Solar: 907 W, 29.2% efficiency n-type TOPCon–perovskite tandem module tested by TÜV SÜD

Summary:

Per pv magazine Global (June 1, 2026), Trina Solar unveiled a 907 W n-type TOPCon–perovskite tandem module with 29.2% full-panel efficiency certified by TÜV SÜD, designed for mass production rather than lab samples, capturing a broader solar spectrum than conventional single-junction silicon. The company plans to accelerate tandem line build-out in 2026, with large commercial shipments expected 2028–2029; prior 210 mm half-cut industrial tandem cells reached 32.6% and 865 W modules with European verification. Recent Nature Photonics work on omnidirectional ionic locking networks reports certified 27.01% single-junction perovskite cells with improved thermal cycling and illumination stability—relevant to tandem stacks.

Links:

• pv magazine Global — Trina Solar announces 907 W tandem solar module with 29.2% efficiency
• Nature Photonics — Omnidirectional ionic locking network for stable perovskite photovoltaics

Commentary:

U.S. and Chinese tandem routes both set new efficiency–power records the same day, shifting competition from lab cells to certifiable, scalable module specs.

IV. Fundamental Research

8. ASKAP J1745−5051: PhD-led team confirms long-period radio transients from accreting white dwarf binary

Summary:

Per Phys.org and the University of Sydney (June 1, 2026), an international team led by PhD student Kovi Rose using CSIRO’s ASKAP radio telescope identified rare binary ASKAP J1745−5051: an Earth-sized, near-solar-mass white dwarf accreting from a ~0.1 solar-mass red dwarf, 1.4-hour orbit, producing periodic radio and X-ray bursts. This is the clearest evidence yet that some long-period radio transients (LPRTs)—only about a dozen known—come from cataclysmic variables rather than slow neutron-star pulsars. It is the second LPRT with regular X-rays and the first with both stellar components and accretion clearly resolved as the periodicity driver. Published in Nature Astronomy (2026, DOI 10.1038/s41550-026-02882-x).

Links:

• Phys.org — Student astronomer discovers 'Rosetta Stone' for mysterious cosmic signals
• Nature Astronomy — Periodic radio and X-ray emission from an accreting white dwarf binary

Commentary:

A Rosetta Stone for decoding LPRTs—and a repeatable window into extreme plasma and magnetic interactions beyond Earth-bound labs.

9. TransCODE Consortium in Nature defines “peptideins,” surfacing 1,700+ dark-proteome candidates

Summary:

Per Nature, EMBL, and EurekAlert, the international TransCODE Consortium integrated 95,520 proteomics experiments, finding protein-level evidence for ~25% of 7,264 non-canonical open reading frames (ncORFs). It introduces “peptideins”—translated products of indeterminate function between known proteins and non-coding sequence—with 1,785 ncORFs supported in HLA-I immunopeptidomics builds. CRISPR screens show an OLMALINC-derived peptidein essential in ~85% of 485 cancer cell lines tested. Data are public via PeptideAtlas with GENCODE/UniProt annotation pathways. Published in Nature (2026, DOI 10.1038/s41586-026-10459-x).

Links:

• Nature — Expanding the human proteome with microproteins and peptideins
• EMBL — Scientists uncover thousands of new proteins in ‘dark proteome’

Commentary:

Formalizing dark-proteome translation brings overlooked sequences into reference annotation and opens new immunotherapy antigen and drug-target space.

10. NSF reportedly holds new grants to Duke, Harvard, Princeton, Yale; NCAR breakup lawsuit continues

Summary:

Per Nature’s May 28, 2026 exclusive, Scientific American, and the Union of Concerned Scientists, NSF’s Office of Award Management allegedly placed “Future Awards to Organization on Hold” on Duke, Harvard, Princeton, and Yale from April 9, stalling 33 proposals ~91 days on average (vs ~10 days normal), ~85% in math, physics, and engineering; only 13 new awards combined this fiscal year, none to Harvard or Duke since the hold. Separately, a late-May Colorado federal hearing addressed UCAR’s suit over White House/OMB plans to break up NCAR, relocate supercomputing, and “rescope” climate modeling toward weather; disclosed memos target human-caused climate and greenhouse-gas research. The judge pledged a prompt ruling.

Links:

• Nature — Exclusive: NSF puts new research grants to top universities on hold
• Scientific American — Top climate research center at risk of cuts sues Trump administration

Commentary:

Funding politicization and atmospheric-science restructuring are raising uncertainty in U.S. basic-research “soft infrastructure” with global spillovers for collaboration and talent.

Today's Summary

• Space: One week after the New Glenn pad explosion, the Cape range keeps operating while single-pad dependence and investigations still squeeze Artemis commercial landing timelines.
• Oncology: ASCO Monday extends plenary headlines—daraxonrasib in pancreatic cancer, ivonescimab OS in sq-NSCLC, and adjuvant selpercatinib in early RET-positive lung cancer with NEJM backing.
• Public health: ETH/Basel triple therapy offers an antibiotic-sparing route to prevent neonatal E. coli K1 meningitis.
• Energy: Tandem PV and Trina Solar same-day tandem module efficiency/power records point to a 2026–2028 manufacturing window.
• Fundamentals: ASKAP’s white-dwarf Rosetta Stone for LPRTs; TransCODE’s peptidein framework for the dark proteome; NSF/NCAR policy fights over U.S. research governance.

Daily Framing:

Today in the science cycle is a “launch-pad shock plus ASCO precision-oncology triple play, tandem-PV efficiency race, cosmic-signal Rosetta stone and dark proteome, and research-funding politics” day—clinical and industrial milestones up front, foundational discovery and institutional stress behind.

This digest is compiled from live search and is for reference only; facts are as reported by cited sources.
Date: June 1, 2026 (Monday)